Abstract: A fingerprint identification circuit, a display panel, and a control method thereof. A first electrical signal is generated by a light sensation circuit in that fingerprint identification circuit according to the detected optical signal reflected by the finger, potential information of the first electrical signal is stored in a holding circuit, and a second electrical signal for fingerprint identification is output by a scanning circuit according to the potential information of the first electrical signal stored in the holding circuit, so that the fingerprint identification device can complete the collection of the electrical signals output by all the fingerprint identification circuits set by the fingerprint identification device in the case that the residence time of the user's finger is short, thereby supporting the design of fingerprint identification circuits with larger area and higher density in the optical fingerprint identification device.

Abstract: A piston limiting structure, including: a cylinder, a piston, and a flange provided with a limiting piece, the cylinder has a piston hole perpendicular to an axial direction of the cylinder and penetrating through the cylinder, and a projection of the piston hole in a penetrating direction is circular. The piston is disposed in the piston hole in a form-fit manner and is slid in the piston hole in a reciprocating manner. A side wall of the piston is provided with a thrust groove, a bottom surface of the thrust groove forms a thrust surface on the side wall of the piston, and the thrust groove does not penetrate through two ends of the side wall of the piston along an axial length of the piston. The limiting piece abuts against the thrust surface.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a renally impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a renally impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic kidney disease with a GKA.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator and a sodium-glucose cotransporter-2 inhibitor.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a hepatically impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a hepatically impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic liver disease with a GKA.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a renally impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a renally impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic kidney disease with a GKA.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator and a sodium-glucose cotransporter-2 inhibitor.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of an untreated or treatment-resistant diabetes with a glucokinase activator, optionally in combination with a dipeptidyl peptidase-4 inhibitor.

Abstract: Disclosed herein is a system and method for generating a motion-corrected 2D image of a target. The method comprises acquiring a 3D static image of the target before an interventional procedure. During the procedure, a number of 2D real time images of the target are acquired and displayed. A slice of the 3D static image is acquired and registered with one 2D real time image and then the location of the 3D static image is corrected to be in synchrony with body motion. The motion corrected 2D image of the target is then displayed.

Abstract: One object of the present disclosure is to provide an interpolation method for reconstructing an imaged object with the image edge as sharp as possible and the image itself as smooth as possible. An The EM (Expectation Maximization) image reconstruction is provided that suitable for freehand ultrasound systems.